Posaconazole Patent Expiration
Posaconazole is used for preventing and treating fungal infections in severely immunocompromised patients aged 2 years and older. It was first introduced by Schering Corp
Posaconazole Patents
Given below is the list of patents protecting Posaconazole, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Noxafil | US10117951 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Merck Sharp Dohme |
| Noxafil | US5661151 | Tetrahydrofuran antifungals |
Jul 19, 2019
(Expired) | Schering |
| Noxafil | US5661151 | Tetrahydrofuran antifungals |
Jul 19, 2019
(Expired) | Merck Sharp Dohme |
| Noxafil | US5703079 | Tetrahydrofuran antifungals |
Aug 26, 2014
(Expired) | Schering |
| Noxafil | US5703079 | Tetrahydrofuran antifungals |
Aug 26, 2014
(Expired) | Merck Sharp Dohme |
| Noxafil | US6958337 | Crystalline antifungal polymorph |
Oct 05, 2018
(Expired) | Schering |
| Noxafil | US8263600 | Antifungal composition with enhanced bioavailability |
Apr 01, 2022
(Expired) | Schering |
| Noxafil | US8410077 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Merck Sharp Dohme |
| Noxafil | US9023790 | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin | Jul 04, 2031 | Merck Sharp Dohme |
| Noxafil | US9358297 | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin | Jun 24, 2031 | Merck Sharp Dohme |
| Noxafil | US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same | Feb 27, 2033 | Merck Sharp Dohme |
| Noxafil | US9750822 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Merck Sharp Dohme |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Posaconazole Generics
Several generic applications have been filed for Posaconazole. The first generic version for Posaconazole was by Sinotherapeutics Inc and was approved on Aug 21, 2019. And the latest generic version is by Gland Pharma Ltd and was approved on Dec 26, 2023.
Given below is the list of companies who have filed for Posaconazole generic.
1. SPECGX LLC
Specgx Llc has filed for 1 generic for Posaconazole. Given below are the details of the strengths of this generic introduced by Specgx Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | tablet, delayed release | Prescription | ORAL | AB | May 10, 2022 |
2. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 1 generic for Posaconazole. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | tablet, delayed release | Prescription | ORAL | AB | Apr 7, 2022 |
3. BIOCON PHARMA
Biocon Pharma Ltd has filed for 1 generic for Posaconazole. Given below are the details of the strengths of this generic introduced by Biocon Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | tablet, delayed release | Prescription | ORAL | AB | Feb 4, 2022 |
4. AMNEAL
Amneal Pharmaceuticals Llc has filed for 1 generic for Posaconazole. Given below are the details of the strengths of this generic introduced by Amneal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | tablet, delayed release | Prescription | ORAL | AB | Dec 22, 2022 |
5. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 1 generic for Posaconazole. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/ML | suspension | Prescription | ORAL | AB | May 15, 2020 |
6. MYLAN LABS LTD
Mylan Laboratories Ltd has filed for 1 generic for Posaconazole. Given below are the details of the strengths of this generic introduced by Mylan Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG/16.7ML (18MG/ML) | solution | Prescription | INTRAVENOUS | AP | Dec 26, 2023 |
7. GLAND PHARMA LTD
Gland Pharma Ltd has filed for 1 generic for Posaconazole. Given below are the details of the strengths of this generic introduced by Gland Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG/16.7ML (18MG/ML) | solution | Prescription | INTRAVENOUS | AP | Dec 26, 2023 |
8. HETERO LABS LTD III
Hetero Labs Ltd Unit Iii has filed for 1 generic for Posaconazole. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Iii.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | tablet, delayed release | Prescription | ORAL | AB | Dec 8, 2022 |
9. SINOTHERAPEUTICS INC
Sinotherapeutics Inc has filed for 1 generic for Posaconazole. Given below are the details of the strengths of this generic introduced by Sinotherapeutics Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | tablet, delayed release | Prescription | ORAL | AB | Aug 21, 2019 |
10. I 3 PHARMS
I 3 Pharmaceuticals Llc has filed for 1 generic for Posaconazole. Given below are the details of the strengths of this generic introduced by I 3 Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | tablet, delayed release | Prescription | ORAL | AB | Aug 28, 2023 |
11. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 1 generic for Posaconazole. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG/16.7ML (18MG/ML) | solution | Prescription | INTRAVENOUS | AP | Dec 26, 2023 |
12. ENDO OPERATIONS
Endo Operations Ltd has filed for 1 generic for Posaconazole. Given below are the details of the strengths of this generic introduced by Endo Operations.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG/16.7ML (18MG/ML) | solution | Prescription | INTRAVENOUS | AP | May 25, 2022 |
13. AET PHARMA
Aet Pharma Us Inc has filed for 1 generic for Posaconazole. Given below are the details of the strengths of this generic introduced by Aet Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | tablet, delayed release | Prescription | ORAL | AB | Feb 1, 2021 |
14. FRESENIUS KABI USA
Fresenius Kabi Usa Llc has filed for 1 generic for Posaconazole. Given below are the details of the strengths of this generic introduced by Fresenius Kabi Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG/16.7ML (18MG/ML) | solution | Prescription | INTRAVENOUS | AP | Dec 26, 2023 |
15. WESTMINSTER PHARMS
Westminster Pharmaceuticals Llc has filed for 1 generic for Posaconazole. Given below are the details of the strengths of this generic introduced by Westminster Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | tablet, delayed release | Prescription | ORAL | AB | Jun 20, 2023 |
16. ACTAVIS LABS FL INC
Actavis Laboratories Fl Inc has filed for 1 generic for Posaconazole. Given below are the details of the strengths of this generic introduced by Actavis Labs Fl Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG | tablet, delayed release | Discontinued | ORAL | N/A | Nov 30, 2022 |